Skip to Content

Ipratropium Nasal Dosage

Medically reviewed on August 28, 2017.

Applies to the following strengths: 21 mcg/inh; 42 mcg/inh

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Rhinorrhea

Rhinorrhea Associated with Allergic and Nonallergic Perennial Rhinitis:
0.03%: 2 sprays per nostril 2 to 3 times a day

Rhinorrhea Associated with Seasonal Allergic Rhinitis:
0.06%: 2 sprays per nostril 4 times a day

Rhinorrhea Associated with the Common Cold:
0.06%: 2 sprays per nostril 3 to 4 times a day

Usual Pediatric Dose for Rhinorrhea

Rhinorrhea Associated with Allergic and Nonallergic Perennial Rhinitis:
6 years or older:
0.03%: 2 sprays per nostril 2 to 3 times a day

Rhinorrhea Associated with Seasonal Allergic Rhinitis:
5 years or older:
0.06%: 2 sprays per nostril 4 times a day

Rhinorrhea Associated with the Common Cold:
0.06%:
5 to 11 years: 2 sprays per nostril 3 times a day
12 years or older: 2 sprays per nostril 3 to 4 times a day

Renal Dose Adjustments

Use with caution.

Liver Dose Adjustments

Use with caution.

Precautions

0.03%: Safety and efficacy have not been established in patients younger than 6 years.

0.06%: Safety and efficacy have not been established in patients younger than 5 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-Initial use of the pump requires priming by 7 sprays of the pump.
-If used regularly as recommended, additional priming is not required.
-If it is not used for more than 24 hours, the pump will require 2 sprays; if not used for more than 7 days, the pump will require 7 sprays to reprime.
-Optimum doses vary with response of individual patient.

Storage requirements:
-Keep tightly closed.
-Avoid freezing.

General:
-Safety and efficacy of the 0.06% formulation beyond 4 days in patients with the common cold have not been established.
-Safety and efficacy of the 0.06% formulation beyond 3 weeks in patients with seasonal allergic rhinitis have not been established.

Patient advice:
-Avoid spraying into the eyes.
-Temporary blurring of vision, precipitation or worsening of narrow-angle glaucoma, mydriasis, increased intraocular pressure, acute eye pain or discomfort, visual halos or colored images in association with red eyes from conjunctival and corneal congestion may result if this drug comes into direct contact with the eyes.
-Contact your healthcare provider if this drug comes into contact with the eyes.
-Dizziness, accomodation disorder, mydriasis, and blurred vision may occur and may effect ability to drive or operate heavy machinery.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide